What ChemoSensoryx Biosciences does

ChemoSensoryX Biosciences SA is a Belgian discovery company specializing in chemical communications mediated by human chemosensory receptors, with a primary focus on olfactory receptor (OR) biology. The company operates a proprietary high-throughput screening (HTS) platform built on an exclusive worldwide license from Duke University for cell lines that enable functional expression of the entire repertoire of ~400 human Olfactory Receptors plus over 700 genetic variants. Its technology uses cAMP and calcium second-messenger measurement to identify agonists, antagonists, and enhancers for these receptors, supported by five liquid handling stations, four multimode readers, and two automated epifluorescence microscopes capable of running approximately 1,000 screening assays per week.

The company has built the largest known database of compound-receptor pairs (~80,000 agonist/antagonist couples across a ~7,000-compound chemical library) and has deorphanized more than 120 human ORs, including receptors responsive to musks, sandalwoods, and ambers. Its service and product portfolio covers receptor deorphanization, odor blocker/antagonist identification, odor enhancer/positive allosteric modulator discovery, new odorant compound discovery, formulation and blend optimization, and animal platform implementation. Customers are concentrated in three segments: flavor and fragrance manufacturers (primary), FMCG and personal care companies (deodorants, hair care, laundry, home care), and pharmaceutical firms engaged in oncology and immunology drug discovery via ectopic olfactory receptor research. Revenue is generated through Fee-for-Service (FFS), Full-Time Equivalent (FTE), risk-sharing, and turnkey solution arrangements, with project-based pricing negotiated directly.

On January 13, 2026, ChemoSensoryX was acquired by MANE Group, a family-owned French flavors and fragrances company ranked among the world's top five players. At the time of acquisition, the company employed 11-50 people (13 specifically reported), operated from Louvain-la-Neuve, Belgium, and held €1.6 million in non-dilutive BioWin grant funding through the IT-Targets consortium with Iteos Therapeutics, ImmunXperts, de Duve Institute, and IRIBHM. The acquisition integrates ChemoSensoryX's receptor-based screening technology into MANE's R&D pipeline across 52 R&D centers and 31 production sites globally.

Name

ChemoSensoryx Biosciences

Legal name

ChemoSensoryX Biosciences SA

Website

https://chemosensoryx.be/

Company type

Private

Operating status

Acquired

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Chemosensory Receptor R&D Services

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Small-Molecule Analytical Development & Method Validation (CMC) (HLAGAHAF), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Olfactory receptor screening
• High-throughput screening
• Flavor fragrance R&D
• Malodor counteraction
• Chemosensory discovery

Headquarters

HQ city

Louvain-la-neuve

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Fee-for-Service (FFS) R&D Programs: Sets up specific R&D programs with customers using flexible business models (Fee For Service) to solve the customer's specific sensory needs. Custom action plans with scientific work plans and deliverables.
2. Full-Time Equivalent (FTE) Engagement: Provides scientific expertise on a per-FTE basis for customer R&D projects, with flexible engagement terms including risk-sharing arrangements.
3. Turnkey Solutions / Internal Research Products: Delivers turnkey solutions directly when customer needs match ChemoSensoryX's internal research programs and available proprietary solutions, including pre-identified odor blockers, enhancers, and new odorant compounds.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

ChemoSensoryx Biosciences operates a proprietary High-Throughput Screening platform built on an exclusive worldwide license from Duke University, enabling functional expression of the full repertoire of human Olfactory Receptors (and other chemosensory receptors) and screening of compounds against them. The company sells B2B R&D services and turnkey solutions for receptor deorphanization, odor blocker/antagonist identification, odor enhancer discovery, new odorant compound discovery, formulation optimization, and drug discovery applications to flavor & fragrance, FMCG, and pharmaceutical customers.

Product overview

ChemoSensoryx Biosciences is a discovery company offering products and services related to chemical communications mediated by human chemosensory receptors. The company operates its patented High-Throughput Screening (HTS) Platform as its core technology, providing services including receptor deorphanization, odor blocker/antagonist identification, odor enhancer discovery, new odorant compound discovery, and formulation/blend optimization. The company has developed the only robust technology for functional expression of human Olfactory Receptors (ORs) under exclusive worldwide license from Duke University. Applications span malodor counteraction, fragrance enhancement, taste modulation, and drug discovery in pharmaceutical markets. The company was acquired by MANE Group in January 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• High-Throughput Screening (HTS) Platform

Quantifiable outcome

• Receptor-guided biotechnology reduced sourcing costs for overharvested botanicals by 20–60% in pilot programs (2024–2026)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered flagship, core, supporting and major.

• MANE GroupflagshipStrategic or Co-development Partner · 13 January 2026MANE Group (top 5 global flavors and fragrances company, family-owned, France) acquired ChemoSensoryX in January 2026 to strengthen innovation in molecular mechanisms of chemosensory perception. The acquisition brings receptor-based screening and predictive modelling capabilities to MANE's R&D pipeline, supporting odor control, taste modulation, olfactory receptor formulation, and trigeminal sensory effects.
• Duke UniversitycoreTechnology or IntegrationChemoSensoryX holds an exclusive worldwide license from Duke University for proprietary cell lines and High-Throughput-Screening systems enabling functional expression of human Olfactory Receptors. This forms the foundation of the company's entire technology platform.
• CertechsupportingStrategic or Co-development PartnerPartnership with Certech, a research center specializing in quantitative and qualitative assessment of odors, for human sensory evaluation of identified malodor antagonists. ChemoSensoryX's in vitro findings are validated through Certech's sensory testing capabilities.
• Iteos Therapeutics S.A.majorStrategic or Co-development PartnerPartnership within the BioWin IT-Targets consortium (€1.6 million grant) focused on identifying innovative drug candidates and biomarkers for immunotherapy of cancer. ChemoSensoryX contributes its unique sensory GPCR technology platform to explore therapeutic potential of olfactory receptors in oncology.
• ImmunXperts S.A.majorStrategic or Co-development PartnerConsortium partner in the BioWin IT-Targets project. ImmunXperts contributes expertise with human primary cells in immuno-oncology drug discovery, complementing ChemoSensoryX's receptor screening platform.
• de Duve InstitutemajorStrategic or Co-development PartnerConsortium partner in the BioWin IT-Targets project. The institute contributes in-depth tumor immunology expertise to the collaboration focused on GPCR-based immunotherapy target identification.
• IRIBHM (Institut de Recherche en Biologie Moléculaire Humaine)majorStrategic or Co-development PartnerConsortium partner in the BioWin IT-Targets project. IRIBHM contributes expertise in GPCR discovery and validation, working with ChemoSensoryX's sensory GPCR technology platform for oncology applications.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Axxam: Italian CRO specializing in high-throughput screening for ion channels and GPCRs. Comparable discovery-services business model and screening-platform technology overlap with ChemoSensoryX's HTS infrastructure.
• Domain Therapeutics: French GPCR drug discovery biotech focused on immuno-oncology and CNS. Comparable as a European GPCR-specialty discovery company with pharma partnership-driven business model.
• Senomyx: Senomyx pioneered chemosensory receptor (including olfactory and taste GPCR) screening for flavors and fragrances before being acquired by Firmenich in 2018 — the closest historical analogue to ChemoSensoryX's model and acquisition pathway into a top-tier F&F house.
• Sosei Heptares: Japan/UK-based GPCR-focused drug discovery company using structure-based design. Directly comparable as a GPCR-specialist biotech platform with pharma licensing economics.
• Confo Therapeutics: Belgian GPCR-focused biotech developing conformation-specific antibody and small-molecule therapeutics. Same country, overlapping GPCR expertise, and a directly comparable Belgian biotech CRO/discovery profile.

Broad incumbents

• International Flavors & Fragrances (IFF): Top-five global F&F company with a Health & Biosciences division. Overlaps with ChemoSensoryX across F&F R&D services and adjacent bio-based ingredient discovery.
• Symrise: Top-five global F&F company with significant pet food, food, and beverage bioscience capabilities. Operates adjacent discovery platforms serving overlapping end-markets.
• dsm-firmenich: Top global flavors and fragrances company formed from the DSM-Firmenich merger; acquired Senomyx in 2018. Operates an integrated bioscience division that overlaps with ChemoSensoryX's F&F discovery offering at a vastly larger scale.
• Givaudan: World's largest flavors and fragrances company with significant in-house bioscience and taste & well-being R&D. Serves the same end-customers as ChemoSensoryX and operates competing proprietary discovery programs.
• Eurofins: Global life-sciences testing services group with fragrance and sensory testing capabilities. Comparable as a large-scale analytical services platform relevant to ChemoSensoryX's screening and characterization business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChemoSensoryx Biosciences